BI unveils new data backing IPF drug Ofev
Two new analyses of data from late-stage trials of Boehringer Ingelheim’s lung drug Ofev presented at CHEST 2016 lend further weight to the body of evidence backing its effectiveness in people with idiopathic pulmonary fibrosis.
Read More
